TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M

TriSalus Life Sciences, Inc.

2026-Q1 EPS reported $0.03 revenue$8,899,000

Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.
Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.
2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.
Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.